ChemicalBook > Product Catalog >API >Nervous system drugs >Antipsychotics >Aripiprazole

Aripiprazole

Aripiprazole Suppliers list
Company Name: HubeiwidelychemicaltechnologyCo.,Ltd
Tel: 18627774460
Email: faith@widelychemical.com
Products Intro: Product Name:Aripiprazole
CAS:129722-12-9
Purity:0.99 Package:4/5kg 4/5kg Aluminum Hearing
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Email: sales@capotchem.com
Products Intro: Product Name:Aripiprazole
CAS:129722-12-9
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Henan DaKen Chemical CO.,LTD.
Tel: +86-371-55531817
Email: info@dakenchem.com
Products Intro: Product Name:Aripiprazole
CAS:129722-12-9
Purity:99% Package:100g,500g,1KG,10KG,100KG
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:129722-12-9
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Nanjing ChemLin Chemical Industry Co., Ltd.
Tel: 025-83697070;product@chemlin.com.cn
Email: product@chemlin.com.cn
Products Intro: CAS:129722-12-9
Purity:98% Package:g-Kg Remarks:White to white powder

Lastest Price from Aripiprazole manufacturers

  • Aripiprazole
  • US $2.00 / kg
  • 2019-07-06
  • CAS:129722-12-9
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 100kg
Aripiprazole Basic information
Outline EU approves aripiprazole for treatment of schizophrenia Metabolize Toxicity Drug Interactions Adverse reactions Uses
Product Name:Aripiprazole
Synonyms:ARIPIPRAZOLE;ARIPIPRAZOLE-D8;ABILIFY;ABILITAT;7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril;OPC 14597;OPC 31;7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone
CAS:129722-12-9
MF:C23H27Cl2N3O2
MW:448.39
EINECS:603-355-5
Product Categories:API;Active Pharmaceutical Ingredients;INORGANIC & ORGANIC CHEMICALS;Heterocycles;Heterocyclic Compounds;Chemistry;Intermediates & Fine Chemicals;Neurochemicals;Pharmaceuticals;Isotope Labeled Compounds
Mol File:129722-12-9.mol
Aripiprazole Structure
Aripiprazole Chemical Properties
Melting point 139°C
Boiling point 646.2±55.0 °C(Predicted)
density 1.263±0.06 g/cm3(Predicted)
storage temp. -20°C Freezer
solubility DMSO: soluble5mg/mL, clear (warmed)
form powder
pka14.42±0.20(Predicted)
color white to beige
Merck 14,785
InChIKeyCEUORZQYGODEFX-UHFFFAOYSA-N
CAS DataBase Reference129722-12-9(CAS DataBase Reference)
Safety Information
Hazard Codes F,Xn
Risk Statements 11-20/21/22-36
Safety Statements 16-36/37
RIDADR UN 1993C 3 / PGIII
WGK Germany 3
RTECS VC8275950
HS Code 29349990
Hazardous Substances Data129722-12-9(Hazardous Substances Data)
ToxicityTDLo ivn-dog: 0.03 mg/kg/10M TXAPA9 173,120,2001
MSDS Information
ProviderLanguage
Aripiprazole English
Aripiprazole Usage And Synthesis
OutlineAripiprazole is a new kind of highly lipid soluble quinoline derivatives, its pharmacological effects characteristic is that it is not only the postsynaptic dopamine D 2 receptor antagonist, but also the presynaptic dopamine D 2 receptor agonist,it can also excite D 1, D 3, D 4 receptors ; it has dual effect of partial activation or receptor antagonistic on 5-HT 1A receptor ; it has a completely antagonistic action on the 5-HT 2A receptor. This feature is different from the first generation, and atypical antipsychotics which belong to the second-generation antipsychotic drugs, and therefore it is called dopamine system stabilizer or third generation antipsychotic. Since it is sold in the market, it is mainly used in clinical schizophrenia, treatment of affective disorders and other psychiatric disorders. According to the literature, aripiprazole has significant effects on schizophrenia positive and negative symptoms and anxiety, depression, cognitive function , while higher safety. It was also reported that the drug can also treat other mental disorders, such as mood disorders manic episodes, senile dementia associated with mental disorders, anxiety disorders, children's behavioral disorders, depression.
EU approves aripiprazole for treatment of schizophreniaNowadays,Bristol-Myers Squibb and Otsuka Pharmaceutical Company announced that the European Union has approved Abilify (aripiprazole) in the treatment of schizophrenia listing application.
Schizophrenia affects 1% of the global population, and more in young adults. Schizophrenia affects thinking, emotional control and decision-making ability of the patient. Schizophrenia-positive patients will have symptoms such as hallucinations and delusions, patients with negative symptoms are social withdrawal, lack of emotional changes.
In 2002 the FDA approved Abilify for the treatment of schizophrenia, which has five dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg and 30 mg, since its approval, in the United States ,a 1.8 million Abilify prescriptions have opened. aripiprazole approved by The EU has four sizes: 5 mg, 10 mg, 15mg and 30 mg.
Aripiprazole as an kind of antipsychotic drugs, in rare cases it may be associated with life-threatening neuroleptic malignant syndrome induced (NMS), also be associated with tardive dyskinesia (TD) have some relevance. Studies have shown that atypical antipsychotics may lead to hyperglycemia, although the study did not examine aripiprazole, but the relationship between hyperglycemia and aripiprazole remains uncertain, therefore, patients in treatment should be carried out blood glucose monitoring.
Patients before receiving aripiprazole treatment should be inform the doctor the physical condition and current drug situation . Aripiprazole should be used with caution in patients with a history of epilepsy aripiprazole.
In short-term clinical studies, the most common adverse reactions of aripiprazole compared with placebo groups are: headache (32%: 25%), anxiety (25%: 24%), insomnia (24%: 19%), nausea (14%: 10%), vomiting (12%: 7%), somnolence (11%: 8%), lightheadedness (11%: 7%), restlessness (10%: 7%) and constipation (10% :8%). A double-blind 26-week clinical study showed that there was higher incidence of tremor in aripiprazole group , it is 9%, only 1% while in the placebo group, slight tremor but tolerable , but also often led to discontinuation.
MetabolizeMetabolic pathway of aripiprazole is mainly through three kinds of biotransformation: dehydrogenation, hydroxylation and N-dealkylation. In vitro studies have shown, CYP3A4 and CYP2D6 are the two enzymes of the metabolism of the product , CYP3A4 and CYP2D6 are responsible for dehydrogenation and hydroxylation, and N-dealkylation is caused by CYP3A4 catalysis. Thus, when there is presence affecting two enzymatic activities and number of drugs, the amount of aripiprazole should be adjusted . In the steady state, pharmacokinetics of the product is proportional to dose. Single oral dose of 14C-labeled product showed that 55% of metabolites excreted through the feces, 25% excreted in urine and 18% of the original drug from the feces, 1% of the original drug excreted in the urine.
The above information is edited by the chemicalbook of Tian Ye.
ToxicityLong-term toxicity: long-term toxicity study at a dose of 60 mg/kg for 26 weeks and 2-year carcinogenicity study at dose of 40 and 60mg/kg showed that this product caused retinal degeneration in rats. It showed no evidence of retinal degeneration in mice and monkey trials. Its mechanism of action has not been further researched, it is not shown that these findings is associated with human risks .
Carcinogenicity: In female mice, the daily 3~30mg/kg dose (based on surface area, respectively, is 0.5 to 5 times the MRHD; calculated by AUC, respectively, MRHD plasma concentrations of 0.1 to 0.9 times) leads to increasing incidence of pituitary tumors, breast cancer and skin cancer adenoacanthoma ; in female rats, the daily 10mg/kg dose (based on surface area is 3 times the MRHD; calculated by AUC, is MRHD plasma concentrations 0.1 times) causes increasing incidence of breast fibrous tumor ,daily 60mg/kg dose (based on surface area, is 19 times the MRHD; calculated by AUC, is MRHD plasma concentrations 14 times) causes increasing incidence of adrenocortical cancer and adrenal tumors .
Mutagenicity: in vitro bacterial reverse mutation assay, in vitro bacterial DNA recovery test, mouse lymphoma cells in vitro gene mutation test, Chinese hamster lung cells in vitro chromosomal aberration test, in vivo micronucleus test in mice and rats Unscheduled DNA synthesis test mutagenicity of this product. As a result, there is a positive response in the mouse micronucleus test in vivo, however, the positive reaction is considered to be independent to the mechanism of human .
Drug Interactions1.It should be used with caution in combination with drugs acting on the central nervous system and alcohol.
2. aripiprazole has possibility of enhancing the role of certain antihypertensive drugs.
3. CYP3A4 inducer will result in elevated aripiprazole clearance and lower blood concentration, CYP3A4 inhibitor azole) or CYP2D inhibitors can inhibit aripiprazole elimination, increase plasma concentration.
Adverse reactions The most common adverse reactions during treatment are headache, anxiety and insomnia. Rare adverse reactions are child blood sugar, even hyperglycemia.
UsesAntipsychotics
DescriptionAripiprazole was launched for the treatment of psychoses including schizophrenia and offers a novel mechanism of action as a partial D2 receptor agonist. Aripiprazole can be synthesized in three steps beginning by the condensation of 7-hydroxy-1,2,3,4- tetrahydroquinolin-2-one with 1 ,Cdibromobutane followed by reaction with 1-(2,3- dichlorophenyl)piperazine. Aripiprazole is a significant D2 agonist/antagonist, 5-HT2 antagonist and 5-HT agonist combined with minimal affinity for a,-adrenergic, H1 and M1 receptors. It has a low D4:D2 selectivity ratio and a D2:5-HT2 affinity ratio that exceeds 15; resulting in different pharmacological characteristics compared to other atypical antipsychotics agents such as clozapine. In animal models, aripiprazole inhibits apomorphine-induced stereotypy without causing catalepsy and ptosis. Moreover, in contrast to classical antipsychotics that produce disabling movement disorders, aripiprazole does not cause an upregulation of D2 receptors or an increase in immediate early gene expression of e.g. the c-fos mRNA in the striatum. In patients with acute relapse of schizophrenia, treatment with aripiprazole provided significant improvement in both positive and negative syndrome scale (PANSS) total score in both short- and longterm evaluations. These results were comparable to those observed with haloperidol or risperidone; however, the early response rate was greater with aripiprazole. Aripiprazole was well tolerated with mild to moderate adverse events such as nausea, dizziness, somnolence and weight gain. The rates of extrapyramidal symptoms were lower than with haloperidol, prolactin levels increase has been uncommon and no significant Q-Tc interval prolongation was observed compared with placebo. Finally, studies suggested a minimal impact of aripiprazole administration on total cholesterol levels and on fasting blood sugar in contrast to other antipsychotics. Aripiprazole has a bioavailability of 87%, a tmax of 3-5 h and a half-life time of 48-68 h. Aripiprazole has been found to have linear kinetics and is mainly metabolized via the cytochrome systems CYP2D6 and CYP3A4. It has little effect on the blood levels of other medications; interaction with both lithium and divalproex sodium found minimal impact. Aripiprazole has also been studied in other psychiatric disorders, including bipolar disorders and has shown great efficacy.
Chemical PropertiesColourless Flake Crystalline Solid
OriginatorOtsuka (Japan)
UsesA deuterated version of Aripiprazole, a selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity. Please note that users have reported separation of this compound and aripiprazole under normal-phase and reverse-phase
UsesA selective dopamine D2-receptor antagonist with dopamine autoreceptor agonist activity. Antipsychotic.
Usescerebral vasodilator, antimotion
UsesFor the treatment of schizophrenia and related psychotic disorders.
Manufacturing ProcessTo a solution of 4.06 g of K2CO3 with 400 ml of water was added 40 g of 7- hydroxy-3,4-dihydrocarbostyril [1] and 158 g of 1,4-dibrombutane. The mixture was refluxed for 3 hours. Then it was extracted with dichloremethane, dried with anhydrous MgSO4, the solvent was removed by evaporation. The residue was purified by means of silica gel chromatography (eluent: dichloromethane) and recrystallized from n-hexane-ethanol to yield 50 g of 7- (4-bromobutoxy)-3,4-dihydrocarbostyril, mp 110.5°-110.0°C.
47 g of 7-(4-bromobutoxy)-3,4-dihydrocarbostyril, 35 g of NaJ in 600 ml of acetonitrile was refluxed for 30 minutes. To this suspension was added 40 g of 1-(2,3-dichlorophenyl)piperazine (it was prepareted from 2,3-chloroaniline and di(2-bromoethyl)amine [1]) and 33 ml of triethylamine. The mixture was refluxed for 3 hours. After removing of the solvent, the residue was dissolved in chloroform, washed with water and dried with anhydrous MgSO4. The solvent was removed by evaporation, and residue was recrystallized from ethanol twice to yield 57.1 g of 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]- butoxy}-3,4-dihydrocarbostyril. Melting point: 139.0°-139.5°C.
Brand nameAbilify (Otsuka).
Therapeutic FunctionAntipsychotic
General DescriptionAripiprazole (Abilify). The newest, longactingaripiprazole (an arylpiperazine quinolinone derivative),appears to be partial agonist of D2 receptors (i.e., itstimulates certain D2 receptors while blocking others dependingon their locations in the brain and the concentrationof drug). Bioavailability of aripiprazole is around 87%, with peak plasma concentration attained at 3 to 5 hours afterdosing. It is metabolized by dehydrogenation, oxidative hydroxylation, and N-dealkylation, largelymediated by hepatic CYPs 3A4 and 2D6.
The diphenylbutylpiperidine class can be considered amodification of the fluorobutyrophenone class. Because oftheir high lipophilicity, the compounds are inherently longacting. Pimozide has been approved for antipsychotic use,and penfluridol has undergone clinical trials in the UnitedStates. Overall, side effects for the two compounds resemblethose produced by the fluorobutyrophenones.
General DescriptionAripiprazole, (7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolone,is an atypical antipsychotic that is available in tablets(Abilify), orally disintegrating tablets (Abilify Discmelt), anda 1-mg/mL oral solution. Unlike the other atypical antipsychotics,aripiprazole exhibits partial agonist activity at D2, D3,D4, and 5-HT1A receptors, and antagonist action at 5-HT2A receptors.Although aripiprazole exhibits a low incidence ofEPS, the compound occupies about 95% of striatal D2 receptorsat therapeutic doses. Additionally, aripiprazole does nothave a fast rate of dissociation from D2 receptors. Althoughthe mechanism of action of this compound remains to be elucidated,the atypical profile for aripiprazole may be related toits action at other monoamine receptors.The compoundis well absorbed with peak plasma levels occurring 3 to 5hours after oral administration. Food does not affect absorptionof aripiprazole. Aripiprazole is extensively metabolizedin the liver by the action of CYP2D6 and CYP3A4. The primarymetabolite in humans is dehydroaripiprazole. This metabolite represents about 40% of aripiprazoleat steady state.In the presence of CYP3A4 and CYP2D6 inhibitorsor inducers, dosage adjustments of aripiprazole maybe required. The mean elimination half-lives in extensive andpoor metabolizers are 75 hours and 146 hours, respectively.The major adverse effects of aripiprazole are headache, anxiety,and insomnia.Similar to other atypical antipsychotics,aripiprazole shows an increased risk in mortality in elderlypatients with dementia-related psychosis.Aripiprazoledemonstrates a different pharmacological profile from allother atypical antipsychotics.
HazardA poison.
Safety ProfileA poison by intravenous route.When heated to decomposition it emits toxic vapors ofNOx and Cl-.
Aripiprazole Preparation Products And Raw materials
Raw materials3-Chloroaniline-->1,4-Dibromobutane-->Triethylamine-->3,4-Dihydro-7-hydroxy-2(1H)-quinolinone
Tag:Aripiprazole(129722-12-9) Related Product Information
THIO-ARIPIPRAZOLE,THIO-ARIPIPRAZOLE 7-(4-BROMOBUTOXY)-2(1H)-3,4-DIHYDROQUINOLINONE[INTERMEDIATE FOR ARIPIPRAZOLE],3,4-DIHYDRO-7-(4-BROMOBUTOXY)-2(1H)-QUINOLINONE/INTERMEDIATE OF ARIPIPRAZOLE,3,4-DIHYDRO-7-(4-BROMOBUTOXY)-2(1H)-QUINOLINONE/INTERMEDIATE OF ARIPIPRAZOLE,7-(4-BROMOBUTOXY)-2(1H)-3,4-DIHYDROQUINOLINONE[INTERMEDIATE FOR ARIPIPRAZOLE] Aripiprazole1-(2,3)Dichlorophenyl)PiperazineBase,Aripiprazole1-(2,3)Dichlorophenyl)PiperazineBase DEHYDROARIPIPRAZOLE, HYDROCHLORIDE Aripiprazole,Anti-Psychotic,Aripiprazole,Anti-Psychotic 7-(4-BROMOBUTOXY)-3,4-DIHYDROQUINOLINE-2(1H)-ONE ( ARIPIPRAZOLE),7-(4-BROMOBUTOXY)-3,4-DIHYDROQUINOLINE-2(1H)-ONE ( ARIPIPRAZOLE) 7-(4-bromobutoxy)-3,4-dihydro-2 (1H)-quinolione (intermediate of aripiprazole),7-(4-bromobutoxy)-3,4-dihydro-2 (1H)-quinolione (intermediate of aripiprazole) DEHYDRO ARIPIPRAZOLE,DEHYDRO ARIPIPRAZOLE 1-(4-PHENOXYBUTYL)PIPERAZINE 1-(2-Chlorophenyl)piperazine hydrochloride Aripiprazole N1,N1-DIMETHYL-2,3-DICHLOROANILINE 4-PROPOXYACETANILINE 1-(4-HYDROXYBUTYL)-4-METHYLPIPERAZINE 7-HYDROXY-3,4-DIHYDRO-2(1H)QUINOLINONE//INTERMEDIATE OF ARIPIPRAZOLE,7-HYDROXY-3,4-DIHYDRO-2(1H)QUINOLINONE//INTERMEDIATE OF ARIPIPRAZOLE 7-METHOXY-1,2,3,4-TETRAHYDRO-QUINOLINE HYDROCHLORIDE Aripiprazole impurity 20 8-(2,3-Dichlorophenyl)-8-aza-5-azoniaspiro[4.5]decane BroMide